Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab and Golimumab Combination in Ulcerative Colitis
NCT03662542Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2018
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of guselkumab in ulcerative colitis (UC) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants Who Achieved Clinical Response at Week 12. Started Nov 2018; status: completed.
02
Drugs
guselkumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03662542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03662542.